Stockscreener 앱 받기
12.35
7.39%
0.85
시간 외 거래:
12.34
-0.010
-0.08%
전일 마감가:
$11.50
열려 있는:
$11.7
하루 거래량:
1.72M
Relative Volume:
0.62
시가총액:
$1.66B
수익:
$66.50M
순이익/손실:
$-100.52M
주가수익비율:
-13.48
EPS:
-0.9165
순현금흐름:
$-146.77M
1주 성능:
-2.22%
1개월 성능:
+0.24%
6개월 성능:
+80.82%
1년 성능:
+571.20%
1일 변동 폭
$11.50
$12.46
1주일 범위
$10.80
$12.60
52주 변동 폭
$1.03
$13.60
Tango Therapeutics Inc Stock (TNGX) Company Profile
명칭
Tango Therapeutics Inc
전화
(857) 320-4900
주소
201 BROOKLINE AVENUE, BOSTON
Compare TNGX vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TNGX
Tango Therapeutics Inc
|
12.35 | 1.55B | 66.50M | -100.52M | -146.77M | -0.9165 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Tango Therapeutics Inc Stock (TNGX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-18 | 개시 | Wolfe Research | Peer Perform |
| 2025-08-19 | 개시 | Piper Sandler | Overweight |
| 2024-07-17 | 개시 | Jefferies | Buy |
| 2024-04-04 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-02-12 | 개시 | Piper Sandler | Overweight |
| 2023-12-08 | 개시 | B. Riley Securities | Buy |
| 2022-10-20 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2021-09-20 | 개시 | SVB Leerink | Outperform |
모두보기
Tango Therapeutics Inc 주식(TNGX)의 최신 뉴스
Earnings To Watch: Tango Therapeutics Inc (TNGX) Reports Q4 2025 Result - GuruFocus
Investment Firm Bets Big on TNGX Stock With $9.5 Million Purchase, According to Recent SEC Filing - The Motley Fool
TD Cowen Health Care Conference - marketscreener.com
Examining the Future: Tango Therapeutics's Earnings Outlook - Benzinga
TNGX Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Tango Therapeutics Stock Hits Day Low of $10.90 Amid Price Pressure - Markets Mojo
Barclays Global Healthcare Conference - marketscreener.com
Leerink Partners Global Healthcare Conference - marketscreener.com
Insider Sell Alert: Adam Crystal Sells Shares of Tango Therapeutics Inc (TNGX) - GuruFocus
Adam Crystal Sells 54,345 Shares of Tango Therapeutics (NASDAQ:TNGX) Stock - MarketBeat
Tango Therapeutics Officer Sells Shares - TradingView
Tango Therapeutics (TNGX) R&D president sells 54,345 company shares - Stock Titan
Investment Review: Can Tango Therapeutics Inc be recession proofMarket Volume Summary & Low Risk High Win Rate Stock Picks - baoquankhu1.vn
Stifel reiterates Tango Therapeutics stock rating at Buy - Investing.com Australia
Stifel reiterates Tango Therapeutics stock rating at Buy By Investing.com - Investing.com Canada
Tango Therapeutics (NASDAQ:TNGX) Trading Down 10.4%Here's What Happened - MarketBeat
Adam Crystal sells 18,452 shares; Form 144 lists 54,345 RSUs (TNGX) - Stock Titan
Tango Therapeutics (TNGX) Price Target Increased by 11.32% to 15.19 - Nasdaq
Tango Therapeutics Hits New 52-Week High of $13.60, Up 77.79% - Markets Mojo
Tango Therapeutics Achieves 423.87% Return, Emerges as a Multibagger Stock in Biotechnology Sector - Markets Mojo
Investment Report: Is Tango Therapeutics Inc in a long term uptrendJuly 2025 Drop Watch & Consistent Profit Focused Trading Strategies - baoquankhu1.vn
Tango Therapeutics (NASDAQ:TNGX) Hits New 1-Year HighHere's Why - MarketBeat
Tango Therapeutics (NASDAQ:TNGX) Now Covered by Mizuho - Defense World
Tango Therapeutics (NASDAQ:TNGX) Trading Up 8.8%Should You Buy? - MarketBeat
Mizuho Initiates Coverage of Tango Therapeutics (TNGX) with Outperform Recommendation - Nasdaq
TNGX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Tango Therapeutics stock hits 52-week high at 13.5 USD - Investing.com
Tango Therapeutics stock hits 52-week high at 13.5 USD By Investing.com - Investing.com UK
Tango Therapeutics (NASDAQ:TNGX) Coverage Initiated at Mizuho - MarketBeat
Mizuho Initiates Tango Therapeutics at Outperform With $19 Price Target - marketscreener.com
Mizuho initiates Tango Therapeutics stock with outperform rating By Investing.com - Investing.com Canada
Mizuho initiates Tango Therapeutics stock with outperform rating - Investing.com
Risk Hedge: Is Columbus Acquisition Corp being accumulated by smart moneyWeekly Earnings Recap & High Win Rate Trade Tips - baoquankhu1.vn
FOMO Trade: How does Tango Therapeutics Inc correlate with NasdaqMarket Performance Summary & Consistent Profit Alerts - baoquankhu1.vn
Tango Therapeutics (TNGX) to Release Earnings on Thursday - MarketBeat
Tango Therapeutics to Report Fourth Quarter 2025 Financial Results and Participate in Three Upcoming Investor Conferences - Bitget
Tango Therapeutics to Report Fourth Quarter 2025 Financial - GlobeNewswire
Readystate Asset Management LP Trims Holdings in Tango Therapeutics, Inc. $TNGX - MarketBeat
Pivotal Vopimetostat Pancreatic Cancer Trial Plan Might Change The Case For Investing In Tango Therapeutics (TNGX) - simplywall.st
Is Tango Therapeutics Inc. stock a smart retirement pickWeekly Investment Summary & Free AI Powered Buy and Sell Recommendations - mfd.ru
Is Tango Therapeutics Inc. a strong candidate for buy and holdTrade Signal Summary & Stock Market Timing Techniques - mfd.ru
Tango Therapeutics CEO Teases Pivotal Vopimetostat Trial, RAS Combo Data at Guggenheim Chat - MarketBeat
Insiders At Tango Therapeutics Sold US$727k In Stock, Alluding To Potential Weakness - 富途牛牛
TNGX PE Ratio & Valuation, Is TNGX Overvalued - Intellectia AI
Tango Therapeutics stock hits 52-week high at $13.47 By Investing.com - Investing.com Australia
Tango Therapeutics (NASDAQ:TNGX) Hits New 52-Week HighShould You Buy? - MarketBeat
Tango Therapeutics stock hits 52-week high at $13.47 - Investing.com
Can Tango Therapeutics Inc. be recession proofJuly 2025 Intraday Action & Weekly Setup with ROI Potential - mfd.ru
TNGX: Pivotal and combination trial data for vopimetostat, plus pipeline updates, are expected this year - TradingView
TNGX: Major clinical milestones for vopimetostat and pipeline updates are expected this year - TradingView
Published on: 2026-02-12 23:58:23 - baoquankhu1.vn
Tango Therapeutics Inc (TNGX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.11%
6.00%
자본화:
|
볼륨(24시간):